Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL434566 | 0.95 | TSHR (0.61) | TSHRLMNAALOX12ACHECHRM2 | |
| Toluene SCHEMBL6659437 | 0.93 | LMNA (0.52) | TSHRLMNAALOX12ACHECHRM2 | |
| Toluene SCHEMBL28280046 | 0.92 | TSHR (0.58) | TSHRLMNAALOX12ACHECHRM2 | |
| Toluene SCHEMBL4266725 | 0.92 | TSHR (0.58) | TSHRLMNAALOX12ACHECHRM2 | |
| Toluene SCHEMBL3278606 | 0.92 | LMNA (0.58) | TSHRLMNAALOX12ACHECHRM2 | |
| Toluene SCHEMBL7694570 | 0.89 | LMNA (0.48) | TSHRLMNAALOX12ACHECHRM2 | |
| Toluene SCHEMBL18186092 | 0.89 | ACHE (0.48) | TSHRLMNAALOX12ACHECHRM2 | |
| Toluene SCHEMBL2022367 | 0.89 | LMNA (0.48) | TSHRLMNAALOX12ACHECHRM2 | |
| Toluene SCHEMBL6944293 | 0.89 | LMNA (0.48) | TSHRLMNAALOX12ACHECHRM2 | |
| Toluene SCHEMBL28762260 | 0.87 | TSHR (0.46) | TSHRLMNAALOX12ACHECHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338697-A1 | LYSOPHOSPHATIDYLCHOLINE COMPOSITIONS | AKER BIOMARINE HUMAN INGREDIENTS AS (NO) | 2021-11-04 | — | — | US | disclosed |
| US-11065267-B2 | Lysophosphatidylcholine compositions | AKER BIOMARINE ANTARCTIC AS (NO) | 2021-07-20 | — | — | US | disclosed |
| US-20190201424-A1 | LYSOPHOSPHATIDYLCHOLINE COMPOSITIONS | AKER BIOMARINE HUMAN INGREDIENTS AS (NO) | 2019-07-04 | — | — | US | disclosed |
| CN-103524401-B | A kind of synthetic method of (2R, 4R)-4-methyl-2 piperidine carboxylic acid | JIANGSU BAOZONG BAODA PHARMACEUTICAL CO.,LTD. (CN) | 2016-01-20 | — | — | CN | disclosed |
| CN-103524401-A | Synthetic method for (2R, 4R)-4-methyl-2-piperidinecarboxylic acid | JIANGSU BAOZONG BAODA PHARMACEUTICAL CO LTD | 2014-01-22 | — | — | CN | disclosed |
| EP-1705169-A2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | Hormos Medical Ltd. (FI) | 2006-09-27 | — | — | EP | disclosed |
| EP-1235776-B1 | TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | HORMOS MEDICAL CORP (FI) | 2006-02-08 | — | — | EP | disclosed |
| US-6875775-B2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD (FI) | 2005-04-05 | — | — | US | disclosed |
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD. | 2003-12-04 | — | — | US | disclosed |
| US-6576645-B1 | Such as 3-(4-chloro-1-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)--2-phenylbut-1 -enyl)phenol; producing tissue specific estro-genic and/or antiestrogenic effect | HORMOS MEDICAL OY LTD (FI) | 2003-06-10 | — | — | US | disclosed |
| EP-1235776-A1 | TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Hormos Medical Corporation (FI) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001036360-A1 | TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | HORMOS MEDICAL CORPORATION (FI) | 2001-05-25 | — | — | WO | disclosed |
| US-4997842-A | Antiarrhythmia | WARNER-LAMBERT CO. (US) | 1991-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | ESR2, ESR1, GPER1 | TSHR 59/4885LMNA 4585/4885ALOX12 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.